Collaborative Wealth Managment Inc. Sells 399 Shares of Johnson & Johnson (NYSE:JNJ)

Collaborative Wealth Managment Inc. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 16.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,089 shares of the company’s stock after selling 399 shares during the period. Collaborative Wealth Managment Inc.’s holdings in Johnson & Johnson were worth $328,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. AGF Management Ltd. raised its holdings in Johnson & Johnson by 49.8% during the 4th quarter. AGF Management Ltd. now owns 646,377 shares of the company’s stock valued at $101,313,000 after buying an additional 214,745 shares during the last quarter. Valley Wealth Managers Inc. boosted its holdings in shares of Johnson & Johnson by 1.9% during the fourth quarter. Valley Wealth Managers Inc. now owns 119,311 shares of the company’s stock worth $18,701,000 after purchasing an additional 2,170 shares during the period. Cary Street Partners Investment Advisory LLC increased its holdings in Johnson & Johnson by 1.2% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 114,494 shares of the company’s stock valued at $17,946,000 after purchasing an additional 1,381 shares during the period. Buckingham Capital Management Inc. raised its position in Johnson & Johnson by 8.2% during the 4th quarter. Buckingham Capital Management Inc. now owns 11,585 shares of the company’s stock valued at $1,816,000 after purchasing an additional 882 shares during the last quarter. Finally, Kinsale Capital Group Inc. lifted its holdings in Johnson & Johnson by 36.3% in the 4th quarter. Kinsale Capital Group Inc. now owns 24,744 shares of the company’s stock worth $3,878,000 after buying an additional 6,587 shares during the period. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on JNJ shares. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Monday, May 6th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price objective for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Royal Bank of Canada decreased their target price on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating for the company in a research report on Wednesday, April 17th. Morgan Stanley dropped their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $175.86.

Check Out Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $151.36 on Wednesday. The company has a 50 day moving average of $152.63 and a 200 day moving average of $154.99. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97. The firm has a market cap of $364.28 billion, a P/E ratio of 9.44, a PEG ratio of 2.49 and a beta of 0.55.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. Johnson & Johnson’s revenue was up 2.3% compared to the same quarter last year. During the same period last year, the firm posted $2.68 earnings per share. As a group, research analysts expect that Johnson & Johnson will post 10.64 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.28%. The ex-dividend date is Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is 29.68%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.